Juvenile Myelomonocytic Leukemia
📧 Sign up to get email alerts when something new happens for Juvenile Myelomonocytic Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy [Phase 1]
This clinical trial aims to determine the highest tolerated dose of imetelstat when given with fludarabine and cytarabine in children with r…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia [Phase 1, Phase 2]
A Phase I/II clinical trial evaluating the combination of trametinib and azacitidine for newly diagnosed juvenile myelomonocytic leukemia (J…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study [Phase 1, Phase 2]
PedAL BCU, LLC is conducting a pediatric screening trial to test bone marrow and blood methods in children with relapsed or hard-to-treat ac…
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies [Phase 2]
Phase 2 clinical trial evaluating MT2021-08T, a T-cell receptor alpha/beta-depleted donor peripheral blood stem cell product, for hematologi…
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation [Phase 1]
Phase 1 trial evaluating CIML NK cell infusion for relapse of myeloid disease after hematopoietic cell transplantation; the study is current…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT [NA]
Clinical trial update indicates ongoing recruitment for a study evaluating CD45RA-depleted peripheral stem cell addback to prevent viral or …
-
CLINICAL_TRIALS research · 2025-11-14Clinical Trial Update: HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant [Phase 1]
This clinical trial update describes a Phase 1 study evaluating HA-1 TCR T-cell immunotherapy for relapsed or refractory acute leukemia afte…
-
CLINICAL_TRIALS research · 2025-08-12Clinical Trial Update: Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation [Phase 2]
This clinical trial update describes a Phase 2 study evaluating TCRγδ T cells and memory T cells with selective use of blinatumomab as part …
-
CLINICAL_TRIALS research · 2025-08-11Clinical Trial Update: Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation [Phase 1]
A Phase 1 dose-escalation study of vorinostat after allogeneic hematopoietic cell transplantation is ongoing.
-
CLINICAL_TRIALS research · 2024-08-27Clinical Trial Update: Myeloproliferative Neoplasms (MPNs) Patient Registry
An update on the Myeloproliferative Neoplasms (MPNs) Patient Registry sponsored by University Health Network in Toronto, currently recruitin…
-
CLINICAL_TRIALS research · 2024-06-04Clinical Trial Update: CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant [Phase 1, Phase 2]
This clinical trial update examines using CD34+ malignant stem cell selection for patients receiving allogeneic stem cell transplants in Pha…
-
CLINICAL_TRIALS research · 2011-04-21Clinical Trial Update: Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT) [Phase 4]
A Phase 4 clinical trial update examining busulfan and cyclophosphamide as a conditioning regimen for hematological malignancies, replacing …